April 6, 2018
The drug, crizotinib, targets a genetic defect that is found in around 7,000 breast cancer patients in the UK each year.
It is already used to treat non-small cell lung cancer by shrinking tumours.
Medics hope it can now be “repurposed” for women with the gene-related form of the disease.
Baroness Delyth Morgan, of charity Breast Cancer Now, called the discovery “extremely exciting”.
The new approach targets cells with faulty versions of a protein called E-cadherin.
This protein helps to bind healthy cells together but when defective it causes cancer cells to grow and divide abnormally.
By clicking Submit, you agree to our
Terms And Conditions and have read and acknowledge our Privacy Statement.